ClinicalTrials.gg
CompletedNCT03201965Updated Nov 26, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

A Phase 3 interventional study of Cyclophosphamide and Bortezomib in Amyloidosis, sponsored by Janssen Research & Development, LLC. Completed at 140 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Enrollment
13th of 99
416 · median 45
Started
2017
with 5 others
Phase 3
27 of 141
7 open now
Registered
62nd of 141
by date
Lead sponsor
3 of 141
Janssen Research & Development, LLC

Among the 141 studies in Amyloidosis with a site in United States, this one is the 13th largest by enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2017, is one of 27 in phase 3, and was the 62nd registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Read the detailed description

Participant involved in study for approx. 8 years duration includes Screening Phase (complete clinical evaluation will be done), Treatment Phase (monitoring of adverse events (AEs), laboratory abnormalities and clinical response), Post-Treatment Observation Phase (disease evaluations will be done) and a Long-term Follow-up Phase (Subsequent anticancer treatment, response to subsequent treatment, date of progression and survival status will be obtained every 16 weeks).The primary hypothesis is that daratumumab in combination with CyBorD will improve the overall complete hematological response rate compared to CyBorD alone in AL amyloidosis participants. Safety will be assessed by AEs, laboratory test results, electrocardiogram, vital sign measurements, physical examination, and Eastern Cooperative Oncology Group (ECOG) performance status.

03

Conditions studied

  • Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in congo red stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearance
  • of amyloid light-chain (AL) amyloidosis as defined by at least one of the following:

    1. serum monoclonal (M)-protein greater than or equal (>=) 0.5 grams/deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation [IFE] performed at a central laboratory)
    2. serum free light chain greater than or equal to (>=) 50 milligram/Liter (mg/L) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved free light chains (dFLC) >= 50 mg/L
  • One or more organs impacted by AL amyloidosis according to consensus guidelines
  • (ECOG) Performance Status (PS) 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for AL amyloidosis or multiple myeloma including medications that target CD38, with the exception of 160 mg dexamethasone (or equivalent ) maximum exposure prior to randomization
  • Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >= 60 percent (%) plasma cells in the bone marrow, or hypercalcemia
  • Evidence of significant cardiovascular conditions as specified below:

    1. NT-ProBNP > 8500 nanogram per liter (ng/L)
    2. (NYHA) classification IIIB or IV heart failure
    3. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (eg, prior myocardial infarction with documented history of cardiac enzyme elevation and [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloid cardiomyopathy
    4. Inpatient admission to a hospital for unstable angina or myocardial infarction within the last 6 months prior to first dose or percutaneous cardiac intervention with recent stent within 6 months or coronary artery bypass grafting within 6 months
    5. For participants with congestive heart failure, cardiovascular-related hospitalizations within 4 weeks prior to randomization
    6. Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillators [ICD] is indicated but not placed (participants who do have a pacemaker/ICD are allowed on study)
    7. Screening 12-lead ECG showing a baseline as corrected by Fridericia's formula (QTcF) > 500 milliseconds (msec). Participants who have a pacemaker may be included regardless of calculated QTc interval
    8. Supine systolic blood pressure \< 90 millimeter of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 20 mmHg despite medical management (eg, midodrine, fludrocortisones) in the absence of volume depletion
  • Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted
  • Known to be seropositive for (HIV)
  • Any one of the following:

    1. Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (ie, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded
    2. Known to be seropositive for (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
  • Grade 2 sensory or Grade 1 painful peripheral neuropathy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
416 participants (actual)

Study arms

  • Active comparator
    CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)

    Participants will receive dexamethasone (40 milligrams \[mg\] orally or intravenous \[IV\] dose), followed by cyclophosphamide (300 milligram per meter square \[mg/m\^2\] orally or IV dose), then bortezomib (1.3 mg/m\^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.

    Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone, 40 mg

  • Experimental
    CyBorD plus Daratumumab

    Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m\^2 orally or IV dose weekly) and bortezomib (1.3 mg/m\^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.

    Drug: Daratumumab

Interventions

  • Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.

  • Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.

  • Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

  • Participants will receive 1800 mg of daratumumab subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Complete Hematologic Response (CHR)

    Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain (iFLC) is less than (\<) upper limit of normal (ULN) and serum and urine Immunofixation electrophoresis (IFE) are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for complete response (CR).

    Time frame: Up to 2.4 years

Secondary outcomes

  1. Major Organ Deterioration Progression-Free Survival (MOD-PFS)

    MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first. Per international amyloidosis consensus criteria (IACC), hematologic progression was defined as satisfying any one of the following criteria: 1) From CHR, abnormal free light chain ratio (light chain must be double and \>ULN); 2) From CHR/VGPR/PR, 50 percent (%) increase in serum M-protein to \>0.5 grams per deciliter (g/dL) or 50% increase in urine M-protein to 200 milligrams (mg)/day; 3) free light chain increase of 50% to 100 milligrams (mg)/Liter (L).

    Time frame: From date of first randomization (Day -3) upto 6.5 years

  2. Overall Survival (OS)

    Overall survival (OS) was measured from the date of randomization to the date of the participant's death.

    Time frame: From date of first randomization (Day -3) up to 7.1 years

  3. Organ Response Rate (OrRR) at 6 Months: Cardiac Response

    The Organ Response Rate (OrRR) for heart was defined as the percentage of participants with baseline involvement of the heart who achieved a confirmed organ response in the heart. Cardiac response was defined as as a decrease of \>30% in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and greater than (\>)300 nanogram/Litre (ng/L).

    Time frame: Month 6

  4. Organ Response Rate (OrRR) at 6 Months: Renal Response

    The OrRR for kidney was defined as the percentage of participants with baseline involvement of the kidney who achieved a confirmed renal response in the kidney. Renal response was defined as more than equal to (≥) 30% decrease in proteinuria or proteinuria decreased to \<0.5 grams (g)/24 hours in the absence of renal progression.

    Time frame: Month 6

  5. Organ Response Rate (OrRR) at 6 Months: Liver Response

    The OrRR for liver was defined as the percentage of participants with baseline involvement of the liver who achieved a confirmed liver response in the liver. Liver response was defined as 50% decrease in abnormal alkaline phosphatase value.

    Time frame: Month 6

  6. Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months

    CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain is \< ULN and serum and urine IFE are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for Complete Response (CR).

    Time frame: Month 6

  7. Time to Complete Hematologic Response (CHR)

    Time to CHR was defined as time between the date of randomization and first efficacy evaluation at which the participant has met all criteria for hematologic CR. CHR was primarily defined by negative immunofixation results and normalized free light chain (FLC) parameters.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  8. Time to Cardiac Response

    Time to cardiac response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had cardiac response.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  9. Time to Liver Response

    Time to liver response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had liver response.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  10. Time to Renal Response

    Time to renal response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had renal response.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  11. Time to Subsequent Non-cross Resistant Anti-plasma Cell Therapy

    Time to subsequent non-cross resistant anti-plasma cell therapy was defined as the time from the date of randomization to the start date of subsequent non-cross resistant, anti-plasma cell therapy.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  12. Duration of Complete Hematologic Response (CHR)

    Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased. CHR was primarily defined by negative immunofixation results and normalized FLC parameters.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  13. Hematologic Very Good Partial Response (VGPR) or Better Rate

    Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR. VGPR was defined as the difference between involved iFLC and uFLC after treatment for baseline difference between iFLC and uFLC (dFLC) \>50 milligrams per liter (mg/L): Reduction in the dFLC \<40 mg/L. For Baseline dFLC \< 50 mg/L: more than (\>) 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR was negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow.

    Time frame: From date of first randomization (Day -3) up to 6.5 years

  14. Change From Baseline in the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Fatigue

    The EORTC-QLQ-C30 a 30-question tool was used to assess the overall quality of life (QoL) in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 Global health status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

    Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96

  15. Change From Baseline in the Short Form Health Survey, Version 2, the Mental Component Summary, (SF-36v2 MCS)

    The SF-36 Health Survey was a generic measure of health status. The SF-36 consisted of 36 questions that yield an eight-scale (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) profile of functional health and well-being, as well as 2 physical and mental health summary measures and a preference-based health utility index. The physical component summary (PCS), the mental component summary (MCS), and the 8 domain scores range from zero (0) to 100, with higher scores representing higher level of functioning.

    Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96

  16. Change From Baseline in EORTC QLQ-C30 Global Health Status Score

    The EORTC-QLQ-C30 a 30-question tool was used to assess the overall QoL in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

    Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96

07

Results

Posted Mar 4, 2021

Participant flow

Participant flow — Overall Study
MilestoneRun-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorD
Started28193195
Treated28188193
Completed000
Not completed28193195
Withdrew: Death56547
Withdrew: Lost to follow-up060
Withdrew: Withdrawal by subject3238
Withdrew: Sponsor's decision2099140

Outcome measures

PrimaryPercentage of Participants With Overall Complete Hematologic Response (CHR)

Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain (iFLC) is less than (\<) upper limit of normal (ULN) and serum and urine Immunofixation electrophoresis (IFE) are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for complete response (CR).

Time frame:
Up to 2.4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Complete Hematologic Response (CHR)
percentage of participantsCyBorDDaratumumab Plus CyBorD
Percentage of Participants With Overall Complete Hematologic Response (CHR)18.1 (13.0 to 24.3)53.3 (46.1 to 60.5)
Statistical analysis
  • CyBorD vs Daratumumab Plus CyBorD · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.13 · 95% CI 3.22 to 8.16
SecondaryMajor Organ Deterioration Progression-Free Survival (MOD-PFS)

MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first. Per international amyloidosis consensus criteria (IACC), hematologic progression was defined as satisfying any one of the following criteria: 1) From CHR, abnormal free light chain ratio (light chain must be double and \>ULN); 2) From CHR/VGPR/PR, 50 percent (%) increase in serum M-protein to \>0.5 grams per deciliter (g/dL) or 50% increase in urine M-protein to 200 milligrams (mg)/day; 3) free light chain increase of 50% to 100 milligrams (mg)/Liter (L).

Time frame:
From date of first randomization (Day -3) upto 6.5 years
Reported as:
Median · months
Major Organ Deterioration Progression-Free Survival (MOD-PFS)
monthsCyBorDDaratumumab Plus CyBorD
Major Organ Deterioration Progression-Free Survival (MOD-PFS)30.23 (16.66 to 48.89)NA (NA to NA)
SecondaryOverall Survival (OS)

Overall survival (OS) was measured from the date of randomization to the date of the participant's death.

Time frame:
From date of first randomization (Day -3) up to 7.1 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsCyBorDDaratumumab Plus CyBorD
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryOrgan Response Rate (OrRR) at 6 Months: Cardiac Response

The Organ Response Rate (OrRR) for heart was defined as the percentage of participants with baseline involvement of the heart who achieved a confirmed organ response in the heart. Cardiac response was defined as as a decrease of \>30% in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and greater than (\>)300 nanogram/Litre (ng/L).

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Organ Response Rate (OrRR) at 6 Months: Cardiac Response
Percentage of participantsCyBorDDaratumumab Plus CyBorD
Organ Response Rate (OrRR) at 6 Months: Cardiac Response22.2 (15.1 to 30.8)41.5 (32.5 to 51.0)
SecondaryOrgan Response Rate (OrRR) at 6 Months: Renal Response

The OrRR for kidney was defined as the percentage of participants with baseline involvement of the kidney who achieved a confirmed renal response in the kidney. Renal response was defined as more than equal to (≥) 30% decrease in proteinuria or proteinuria decreased to \<0.5 grams (g)/24 hours in the absence of renal progression.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Organ Response Rate (OrRR) at 6 Months: Renal Response
Percentage of participantsCyBorDDaratumumab Plus CyBorD
Organ Response Rate (OrRR) at 6 Months: Renal Response27.4 (19.5 to 36.6)53.8 (44.4 to 63.1)
SecondaryOrgan Response Rate (OrRR) at 6 Months: Liver Response

The OrRR for liver was defined as the percentage of participants with baseline involvement of the liver who achieved a confirmed liver response in the liver. Liver response was defined as 50% decrease in abnormal alkaline phosphatase value.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Organ Response Rate (OrRR) at 6 Months: Liver Response
Percentage of participantsCyBorDDaratumumab Plus CyBorD
Organ Response Rate (OrRR) at 6 Months: Liver Response7.1 (0.2 to 33.9)40.0 (12.2 to 73.8)
SecondaryPercentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months

CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain is \< ULN and serum and urine IFE are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for Complete Response (CR).

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months
Percentage of participantsCyBorDDaratumumab Plus CyBorD
Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months14.0 (9.4 to 19.7)50.3 (43.0 to 57.5)
SecondaryTime to Complete Hematologic Response (CHR)

Time to CHR was defined as time between the date of randomization and first efficacy evaluation at which the participant has met all criteria for hematologic CR. CHR was primarily defined by negative immunofixation results and normalized free light chain (FLC) parameters.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Days
Time to Complete Hematologic Response (CHR)
DaysCyBorDDaratumumab Plus CyBorD
Time to Complete Hematologic Response (CHR)85.00 (14.0 to 617.0)67.50 (8.0 to 879.0)
SecondaryTime to Cardiac Response

Time to cardiac response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had cardiac response.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Months
Time to Cardiac Response
MonthsCyBorDDaratumumab Plus CyBorD
Time to Cardiac Response4.67 (0.9 to 25.5)3.84 (1.0 to 17.8)
SecondaryTime to Liver Response

Time to liver response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had liver response.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Months
Time to Liver Response
MonthsCyBorDDaratumumab Plus CyBorD
Time to Liver Response10.61 (2.0 to 15.2)4.68 (1.0 to 22.6)
SecondaryTime to Renal Response

Time to renal response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had renal response.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Months
Time to Renal Response
MonthsCyBorDDaratumumab Plus CyBorD
Time to Renal Response3.75 (0.9 to 42.2)1.91 (0.4 to 38.3)
SecondaryTime to Subsequent Non-cross Resistant Anti-plasma Cell Therapy

Time to subsequent non-cross resistant anti-plasma cell therapy was defined as the time from the date of randomization to the start date of subsequent non-cross resistant, anti-plasma cell therapy.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Months
Time to Subsequent Non-cross Resistant Anti-plasma Cell Therapy
MonthsCyBorDDaratumumab Plus CyBorD
Time to Subsequent Non-cross Resistant Anti-plasma Cell Therapy11.30 (8.71 to 21.03)NA (NA to NA)
SecondaryDuration of Complete Hematologic Response (CHR)

Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased. CHR was primarily defined by negative immunofixation results and normalized FLC parameters.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Median · Months
Duration of Complete Hematologic Response (CHR)
MonthsCyBorDDaratumumab Plus CyBorD
Duration of Complete Hematologic Response (CHR)NA (56.74 to NA)NA (NA to NA)
SecondaryHematologic Very Good Partial Response (VGPR) or Better Rate

Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR. VGPR was defined as the difference between involved iFLC and uFLC after treatment for baseline difference between iFLC and uFLC (dFLC) \>50 milligrams per liter (mg/L): Reduction in the dFLC \<40 mg/L. For Baseline dFLC \< 50 mg/L: more than (\>) 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR was negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow.

Time frame:
From date of first randomization (Day -3) up to 6.5 years
Reported as:
Number · Percentage of participants
Hematologic Very Good Partial Response (VGPR) or Better Rate
Percentage of participantsCyBorDDaratumumab Plus CyBorD
Hematologic Very Good Partial Response (VGPR) or Better Rate50.3 (43.0 to 57.5)79.0 (72.6 to 84.5)
SecondaryChange From Baseline in the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Fatigue

The EORTC-QLQ-C30 a 30-question tool was used to assess the overall quality of life (QoL) in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 Global health status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

Time frame:
Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
Reported as:
Least squares mean · Score on scale
Change From Baseline in the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Fatigue
Score on scaleCyBorDDaratumumab Plus CyBorD
Week 43.79 (0.33 to 7.25)2.07 (-1.39 to 5.53)
Week 84.04 (0.50 to 7.58)3.93 (0.44 to 7.42)
Week 126.35 (2.74 to 9.96)2.77 (-0.82 to 6.37)
Week 169.92 (6.25 to 13.60)1.54 (-2.10 to 5.17)
Week 206.83 (3.01 to 10.65)3.87 (0.27 to 7.47)
Week 240.69 (-5.40 to 6.79)0.30 (-3.37 to 3.98)
Week 283.30 (-0.90 to 7.51)2.14 (-4.41 to 8.69)
Week 32-3.14 (-11.77 to 5.49)-4.92 (-8.82 to -1.03)
Week 36-10.25 (-21.95 to 1.45)-12.59 (-20.06 to -5.13)
Week 402.09 (-7.49 to 11.68)-5.39 (-9.34 to -1.43)
Week 441.57 (-9.46 to 12.59)-9.55 (-17.19 to -1.90)
Week 48-2.82 (-8.98 to 3.34)-7.99 (-12.03 to -3.95)
Week 52-1.69 (-9.28 to 5.90)-5.56 (-12.58 to 1.46)
Week 56-1.88 (-10.00 to 6.24)-6.77 (-10.89 to -2.64)
Week 60-2.62 (-10.99 to 5.75)-9.23 (-16.12 to -2.34)
Week 64-3.55 (-13.13 to 6.04)-10.36 (-14.61 to -6.12)
Week 680.84 (-9.63 to 11.30)-5.96 (-11.90 to -0.03)
Week 72-0.44 (-7.55 to 6.67)-11.80 (-16.16 to -7.45)
Week 76-5.08 (-14.68 to 4.51)-8.91 (-15.07 to -2.75)
Week 80-6.00 (-12.96 to 0.97)-10.79 (-15.07 to -6.51)
Week 84-17.23 (-28.87 to -5.58)-10.39 (-16.63 to -4.14)
Week 88-6.71 (-16.34 to 2.91)-9.83 (-14.08 to -5.57)
Week 92-7.43 (-19.78 to 4.92)-12.11 (-18.43 to -5.78)
Week 96-5.75 (-13.87 to 2.37)-8.56 (-13.16 to -3.95)
SecondaryChange From Baseline in the Short Form Health Survey, Version 2, the Mental Component Summary, (SF-36v2 MCS)

The SF-36 Health Survey was a generic measure of health status. The SF-36 consisted of 36 questions that yield an eight-scale (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) profile of functional health and well-being, as well as 2 physical and mental health summary measures and a preference-based health utility index. The physical component summary (PCS), the mental component summary (MCS), and the 8 domain scores range from zero (0) to 100, with higher scores representing higher level of functioning.

Time frame:
Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
Reported as:
Least squares mean · Score on scale
Change From Baseline in the Short Form Health Survey, Version 2, the Mental Component Summary, (SF-36v2 MCS)
Score on scaleCyBorDDaratumumab Plus CyBorD
Week 4-0.43 (-1.95 to 1.09)-0.19 (-1.71 to 1.34)
Week 8-1.09 (-2.64 to 0.46)-1.42 (-2.96 to 0.12)
Week 12-1.86 (-3.44 to -0.28)-0.17 (-1.74 to 1.40)
Week 16-3.15 (-4.76 to -1.54)-0.35 (-1.94 to 1.23)
Week 20-2.36 (-4.04 to -0.68)-0.42 (-1.99 to 1.16)
Week 24-1.84 (-4.50 to 0.82)-0.60 (-2.20 to 1.01)
Week 28-3.26 (-5.10 to -1.42)-0.93 (-3.74 to 1.88)
Week 320.19 (-3.51 to 3.89)0.61 (-1.09 to 2.31)
Week 36-0.45 (-5.47 to 4.57)1.22 (-2.05 to 4.49)
Week 40-0.56 (-4.67 to 3.54)2.02 (0.30 to 3.74)
Week 441.30 (-3.70 to 6.30)1.55 (-1.73 to 4.82)
Week 480.26 (-2.39 to 2.91)2.18 (0.41 to 3.94)
Week 520.69 (-2.57 to 3.94)1.33 (-1.73 to 4.39)
Week 56-0.35 (-3.83 to 3.13)0.91 (-0.88 to 2.71)
Week 602.20 (-1.39 to 5.79)1.32 (-1.64 to 4.28)
Week 64-2.00 (-6.28 to 2.28)2.74 (0.90 to 4.58)
Week 680.68 (-3.81 to 5.17)1.25 (-1.32 to 3.83)
Week 72-1.21 (-4.26 to 1.84)2.03 (0.14 to 3.92)
Week 761.05 (-3.07 to 5.17)0.12 (-2.56 to 2.80)
Week 800.47 (-2.58 to 3.52)2.32 (0.44 to 4.20)
Week 843.21 (-1.77 to 8.19)1.56 (-1.12 to 4.25)
Week 882.12 (-2.35 to 6.59)2.57 (0.72 to 4.42)
Week 92-2.50 (-7.78 to 2.78)1.31 (-1.40 to 4.02)
Week 96-0.03 (-3.61 to 3.55)2.96 (0.96 to 4.96)
SecondaryChange From Baseline in EORTC QLQ-C30 Global Health Status Score

The EORTC-QLQ-C30 a 30-question tool was used to assess the overall QoL in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

Time frame:
Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
Reported as:
Least squares mean · Score on scale
Change From Baseline in EORTC QLQ-C30 Global Health Status Score
Score on scaleCyBorDDaratumumab Plus CyBorD
Week 4-3.02 (-5.89 to -0.14)-2.72 (-5.59 to 0.16)
Week 8-4.15 (-7.09 to -1.21)-3.83 (-6.73 to -0.93)
Week 12-6.00 (-9.01 to -3.00)-1.70 (-4.70 to 1.29)
Week 16-7.17 (-10.23 to -4.11)-2.75 (-5.78 to 0.28)
Week 20-5.46 (-8.65 to -2.27)-2.53 (-5.52 to 0.47)
Week 24-4.26 (-9.43 to 0.92)-0.76 (-3.83 to 2.31)
Week 28-3.81 (-7.34 to -0.29)-1.96 (-7.53 to 3.61)
Week 323.03 (-4.33 to 10.39)1.36 (-1.90 to 4.62)
Week 362.97 (-7.02 to 12.97)3.09 (-3.27 to 9.45)
Week 40-6.13 (-14.31 to 2.05)5.10 (1.79 to 8.41)
Week 44-1.37 (-10.79 to 8.05)0.16 (-6.36 to 6.68)
Week 48-0.71 (-5.94 to 4.52)6.79 (3.40 to 10.17)
Week 52-0.17 (-6.63 to 6.30)8.61 (2.64 to 14.59)
Week 563.62 (-3.30 to 10.54)4.02 (0.56 to 7.49)
Week 602.33 (-4.80 to 9.47)5.85 (-0.02 to 11.71)
Week 64-5.49 (-13.67 to 2.70)8.27 (4.70 to 11.83)
Week 686.19 (-2.75 to 15.14)4.95 (-0.08 to 9.99)
Week 72-4.26 (-10.31 to 1.79)8.94 (5.27 to 12.60)
Week 762.00 (-6.19 to 10.19)10.34 (5.11 to 15.57)
Week 804.13 (-1.79 to 10.06)7.05 (3.45 to 10.65)
Week 843.69 (-6.26 to 13.64)6.85 (1.54 to 12.15)
Week 88-2.95 (-11.16 to 5.26)7.59 (4.01 to 11.16)
Week 923.18 (-7.39 to 13.74)8.08 (2.70 to 13.45)
Week 966.54 (-0.38 to 13.47)8.03 (4.15 to 11.91)

Adverse events

Collected over All cause mortality: From baseline (Day -28) up to 7.1 years; Serious and Other AEs: For CyBorD: From start of treatment (Day 1) up to 30 days after last dose of study drug ( up to 8.33 months). Daratumumab plus CyBorD: From start of treatment (Day 1) up to 30 days after last dose of study drug ( up to 27.7 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In: Daratumumab Plus CyBorD11/28 (39.3%)12/28 (42.9%)27/28 (96.4%)
CyBorD67/193 (34.7%)68/188 (36.2%)181/188 (96.3%)
Daratumumab Plus CyBorD47/195 (24.1%)91/193 (47.2%)184/193 (95.3%)
Most frequent serious events
Showing 10 of 159
Most frequent serious events
EventRun-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorD
FallInjury, poisoning and procedural complications3/280/1880/193
Acute Kidney InjuryRenal and urinary disorders3/281/1883/193
Cardiac FailureCardiac disorders0/288/18814/193
PneumoniaInfections and infestations2/289/18814/193
CellulitisInfections and infestations2/281/1882/193
Cardiac ArrestCardiac disorders0/283/1888/193
SepsisInfections and infestations0/280/1887/193
AnaemiaBlood and lymphatic system disorders1/281/1880/193
Cardiac Failure CongestiveCardiac disorders1/282/1881/193
DiarrhoeaGastrointestinal disorders1/284/1883/193
Most frequent other events
Showing 10 of 118
Most frequent other events
EventRun-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorD
DiarrhoeaGastrointestinal disorders19/2855/18869/193
FatigueGeneral disorders16/2852/18855/193
Oedema PeripheralGeneral disorders14/2866/18871/193
AnaemiaBlood and lymphatic system disorders13/2844/18849/193
DizzinessNervous system disorders13/2826/18831/193
LymphopeniaBlood and lymphatic system disorders12/2828/18837/193
ConstipationGastrointestinal disorders12/2854/18870/193
NauseaGastrointestinal disorders12/2851/18855/193
Upper Respiratory Tract InfectionInfections and infestations10/2821/18850/193
HyperglycaemiaMetabolism and nutrition disorders10/287/18812/193

Baseline characteristics

Age, Continuous
Age, Continuous(years)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
Mean64.8 ± 11.264 ± 9.6662.2 ± 10.1663.2 ± 10.03
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
Female117687174
Male16117108241
Undifferentiated Sex1001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
Hispanic or Latino113923
Not Hispanic or Latino26176179381
Unknown or Not Reported14712
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
American Indian or Alaska Native0213
Asian0343064
Native Hawaiian or Other Pacific Islander0101
Black or African American27615
White25143151319
More than one race0101
Unknown or Not Reported15713
Region of Enrollment
Region of Enrollment(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
AUSTRALIA0151227
BELGIUM0123
BRAZIL07411
CANADA010919
CHINA06612
DENMARK0112
FRANCE0221638
GERMANY011819
GREECE0111627
HUNGARY0224
ISRAEL05611
ITALY0549
JAPAN0131528
MEXICO0112
NETHERLANDS04711
POLAND0224
SOUTH KOREA012820
SPAIN0112132
SWEDEN0213
TURKEY071017
UNITED KINGDOM0448
UNITED STATES284140109
Weight group in Kilograms (Kg)
Weight group in Kilograms (Kg)(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
<=65 kg57462141
>65 to 85 kg127496182
>85 kg11453793
Baseline Major Organ Involvement
Baseline Major Organ Involvement(Participants)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
Baseline Organ Involvement: Heart17137140294
Baseline Organ Involvement: Kidney19114115248
Baseline Organ Involvement: Liver4161535
Number of Organs Involved
Number of Organs Involved(organs)Run-In: Daratumumab Plus CyBorDCyBorDDaratumumab Plus CyBorDTotal
Mean2.0 ± 0.8812.0 ± 1.032.0 ± 0.972.0 ± 0.99

3 further baseline measures are reported on the registry.

08

Study locations

140 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • City of Hope
    Duarte, California 91010, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Stanford University
    Stanford, California 94305, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Winship Cancer Institute Emory University
    Atlanta, Georgia 30322, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215-5418, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School Of Medicine
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Wake Forest University Health Sciences - Cardiovascular Medicine
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health And Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
  • Box Hill Hospital
    Box Hill, 3128, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Az Groeninge
    Kortrijk, 8500, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Sociedade Pernambucana de Combate ao Cancer
    Recife, 50040-000, Brazil
  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
    Rio de Janeiro, 22775 001, Brazil
  • Hospital Sao Rafael
    Salvador, 41253 190, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
    São José do Rio Preto, 15090-000, Brazil
  • Clinica Sao Germano
    São Paulo, 01455 010, Brazil
  • Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE
    São Paulo, 04039-004, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    São Paulo, 05403-010, Brazil
  • Arthur J E Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
  • Alberta Health Services
    Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • London Health Sciences Center
    London, Ontario N6A 5W9, Canada
  • University Health Network UHN Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Peking University First Hospital
    Beijing, 100034, China
  • Peking University People s Hospital
    Beijing, 100044, China
  • First affiliated Hospital of Zhejiang University
    Hangzhou, 310020, China
  • Ruijin Hospital Shanghai Jiao Tong University
    Shanghai, 200025, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Aarhus University Hospital
    Aarhus N, DK-8200, Denmark
  • Dep. of Hematology, Rigshospitalet
    Copenhagen, 2400, Denmark
  • Odense Universitets Hospital
    Odense, 5000, Denmark
  • CHU Dijon
    Dijon, 21000, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • CHU de Limoges - Fédération Hépatologie
    Limoges, 87000, France
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Chu Hotel Dieu
    Nantes, 44035, France
  • Hopital Saint Louis
    Paris, 75475, France
  • Centre hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • CHU De Poitiers
    Poitiers, 86000, France
  • CHU Rangueil
    Toulouse, 31400, France
  • CHU Bretonneau
    Tours, 37044, France
  • CHU de Nancy_ Hopital Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Charite Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Heinrich-Heine-Universität Düsseldorf
    Düsseldorf, 40225, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • HOPA-Hämatologisch-Onkologische Praxis Altona MVZ GmbH
    Hamburg, 22767, Germany
  • Universitaetsklinikum Heidelberg Medizinische Klinik V
    Heidelberg, 69120, Germany
  • Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,
    Tübingen, 72076, Germany
  • Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii
    Würzburg, 97080, Germany
  • Alexandra General Hospital of Athens
    Athens, 11528, Greece
  • University General Hospital of Rio
    Pátrai, 26500, Greece
  • Semmelweis Egyetem I.Belgyogyaszati Klinika
    Budapest, 1083, Hungary
  • Semmelweis Egyetem I.Belgyogyaszati Klinika
    Budapest, 1088, Hungary
  • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
    Budapest, 1097, Hungary
  • Carmel Hospital
    Haifa, 34362, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Assaf Ha'Rofeh Medical Center
    Ẕerifin, 70300, Israel
  • Policlinico di Bari
    Bari, 70124, Italy
  • Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Casa di Cura La Maddalena
    Palermo, 90146, Italy
  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Dipartimento Di Biotecnologie Cellulari Ed Ematologia-Università ''La Sapienza'',Policlinico Umberto I
    Roma, 00161, Italy
  • A.O.U. Città della Salute e della Scienza
    Torino, 10126, Italy
  • Fukushima Medical University Hospital
    Fukushima, 960 1295, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
    Hiroshima, 730-8619, Japan
  • Teine Keijinkai Hospital
    Hokkaido, 006-8555, Japan
  • Kanazawa University Hospital
    Kanazawa, 920 8641, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Kyoto Kuramaguchi Medical Center
    Kyoto, 603-8151, Japan
  • Shinshu University Hospital
    Matsumoto, 390 8621, Japan

Showing the first 100 of 140 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Schonland SO, Gatt ME, Suzuki K, Kim K, Cibeira MT, Bhutani M, Beksac M, Libby EN, Valent J, Hungria V, Rosenzweig MA, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman A, Goodman S, Zonder JA, Lam S, Song KW, Hansen T, Manier S, Roeloffzen WWH, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe EQ, Tran N, Wang J, Chen Y, Vasey SY, Schecter JM, Vermeulen J, Comenzo R, Merlini G. Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis. Blood. 2026 May 12:blood.2025032099. doi: 10.1182/blood.2025032099. Online ahead of print. PubMed 42118698 ↗
  • Suzuki K, Wechalekar AD, Kim K, Shimazaki C, Kim JS, Ikezoe T, Min CK, Zhou F, Cai Z, Chen X, Iida S, Katoh N, Fujisaki T, Shin HJ, Tran N, Qin X, Vasey SY, Tromp B, Weiss BM, Comenzo RL, Kastritis E, Lu J. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. Ann Hematol. 2023 Apr;102(4):863-876. doi: 10.1007/s00277-023-05090-z. Epub 2023 Mar 2. PubMed 36862168 ↗
  • Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Grogan M, Witteles R, Ruberg FL, Maurer MS, Tran N, Qin X, Vasey SY, Weiss BM, Vermeulen J, Jaccard A. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. JACC CardioOncol. 2022 Nov 15;4(4):474-487. doi: 10.1016/j.jaccao.2022.08.011. eCollection 2022 Nov. PubMed 36444227 ↗
  • Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schonland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. PubMed 34192431 ↗
  • Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. PubMed 32244252 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Feb 2020, 28 months.

Results were first posted in Mar 2021, 1 year after primary completion.

Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 74. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2017
First posted
Jun 28, 2017
StartActual
Oct 5, 2017
Primary completionActual
Feb 14, 2020
CompletionActual
Nov 19, 2024
Results first posted
Mar 4, 2021
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03201965
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Oct 5, 2017
Primary completion
Feb 14, 2020
Completion
Nov 19, 2024
Results posted
Mar 4, 2021
Last update
Nov 26, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion